Mesopredator Release by an Emergent Superpredator: A Natural Experiment of Predation in a Three Level Guild

Chakarov N, Krüger O. Mesopredator Release by an Emergent Superpredator: A Natural Experiment of Predation in a Three Level Guild. PLoS ONE. 2010;5(12): e15229.Background: Intraguild predation (IGP) is widespread but it is often neglected that guilds commonly include many layers of dominance within. This could obscure the effects of IGP making unclear whether the intermediate or the bottom mesopredator will bear higher costs from the emergence of a new top predator. Methodology/Principal Findings: In one of the most extensive datasets of avian IGP, we analyse the impact of recolonization of a superpredator, the eagle owl Bubo bubo on breeding success, territorial dynamics and population densities of two mesopredators, the northern goshawk Accipiter gentilis and its IG prey, the common buzzard Buteo buteo. The data covers more than two decades and encompass three adjacent plots. Eagle owls only recolonized the central plot during the second decade, thereby providing a natural experiment. Both species showed a decrease in standardized reproductive success and an increase in brood failure within 1.5 km of the superpredator. During the second decade, territory dynamics of goshawks was significantly higher in the central plot compared to both other plots. No such pattern existed in buzzards. Goshawk density in the second decade decreased in the central plot, while it increased in both other plots. Buzzard density in the second decade rapidly increased in the north, remained unchanged in the south and increased moderately in the center in a probable case of mesopredator release. Conclusions/Significance: Our study finds support for top-down control on the intermediate mesopredator and both top-down and bottom-up control of the bottom mesopredator. In the face of considerable costs of IGP, both species probably compete to breed in predator-free refugia, which get mostly occupied by the dominant raptor. Therefore for mesopredators the outcome of IGP might depend directly on the number of dominance levels which supersede them

A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability

AIM To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. METHODS The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP = 362, MSA = 398), 627 had per protocol images (PSP = 297, MSA = 330). Intra-rater (n = 60) and inter-rater (n = 555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n = 441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. RESULTS Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥ 0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75-0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1-F2; MSA: F2-F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity. CONCLUSIONS The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224